Invitrogen

SARS/SARS-CoV-2 Nucleocapsid Monoclonal Antibody (05)

SARS/SARS-CoV-2 Nucleocapsid Antibody in Immunocytochemistry (ICC/IF)

FIGURE: 1 / 9

SARS/SARS-CoV-2 Nucleocapsid Antibody (MA5-29981) in ICC/IF

Immunofluorescent analysis of SARS-CoV-2 Coronavirus Nucleocapsid protein in SARS-CoV-2 infected Vero E6 cells. Cells were incubated with a SARS/SARS-Cov-2 Coronavirus Nucleocapsid Monoclonal Antibody (5) (Product # MA5-29981) at indicated dilution at 4C overnight, and followed by incubating with F(ab')2-Rabbit anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (Product # A-21204) at a ... View More

SARS/SARS-CoV-2 Nucleocapsid Antibody in Western Blot (WB)

SARS/SARS-CoV-2 Nucleocapsid Antibody in Flow Cytometry (Flow)

Product Image Gallery

Product Details

MA5-29981

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000-1:10,000

View 6 publications 6 publications

Immunohistochemistry (IHC)

View 1 publication 1 publication

Immunohistochemistry (Paraffin) (IHC (P))

1:1,000-1:5,000

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

1:100-1:500

View 6 publications 6 publications

Flow Cytometry (Flow)

1:25-1:100

ELISA (ELISA)

1:1,000-1:2,000

Product Specifications

Species Reactivity

Virus

Published species

Hamster, Human, Non-human primate, Virus

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

Immunogen

Recombinant Human SARS Coronavirus Nucleoprotein/NP Protein

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Protein A

Storage buffer

PBS

Contains

no preservative

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2785780

Product Specific Information

MA5-29981 cross reacts with SARS-Cov-2 (COVID 19) Nucleoprotein in ELISA and WB.

This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%).

This antibody has specificity for Human SARS Coronavirus Nucleoprotein/NP.

Target Information

SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus. The SARS-CoV-2 N protein is an abundant RNA-binding protein critical for viral genome packaging, yet the molecular details that involve this process are poorly understood. N protein contains three dynamic disordered regions that house putative transiently-helical binding motifs. The two folded domains interact minimally such that full-length N protein is a flexible and multivalent RNA-binding protein. SARS-CoV-2 causes illnesses ranging from the common cold to severe diseases.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Reversible rearrangement of the cellular cytoskeleton: A key to the broad-spectrum antiviral activity of novel amphiphilic polymers.

Materials today. Bio

Dabrowska A,Botwina P,Barreto-Duran E,Kubisiak A,Obloza M,Synowiec A,Szczepanski A,Targosz-Korecka M,Szczubialka K,Nowakowska M,Pyrc K

MA5-29981 was used in Immunocytochemistry-immunofluorescence to assess the efficacy and underlying mechanism of the inhibitors using fully differentiated human airway epithelial cultures, wherein near-complete abrogation of viral replication was documented.

Sun Oct 01 00:00:00 EDT 2023

Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response.

iScience

Wang Y,Li P,Xu L,de Vries AC,Rottier RJ,Wang W,Crombag MBS,Peppelenbosch MP,Kainov DE,Pan Q

MA5-29981 was used in Immunocytochemistry-immunofluorescence to demostrate that indomethacin is a pan-coronavirus inhibitor that can simultaneously inhibit virus-triggered inflammatory response.

Fri Sep 15 00:00:00 EDT 2023

Altered microRNA Transcriptome in Cultured Human Airway Cells upon Infection with SARS-CoV-2.

Viruses

Diallo I,Jacob RA,Vion E,Kozak RA,Mossman K,Provost P

MA5-29981 was used in Western Blotting to highlight the modulatory role of miRNAs in the pathogenesis of SARS-CoV-2.

Fri Feb 10 00:00:00 EST 2023

Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.

ACS infectious diseases

Pohl MO,Martin-Sancho L,Ratnayake R,White KM,Riva L,Chen QY,Lieber G,Busnadiego I,Yin X,Lin S,Pu Y,Pache L,Rosales R,Déjosez M,Qin Y,De Jesus PD,Beall A,Yoh S,Hale BG,Zwaka TP,Matsunaga N,García-Sastre A,Stertz S,Chanda SK,Luesch H

Published figure using SARS/SARS-CoV-2 Nucleocapsid monoclonal antibody (Product # MA5-29981) in Immunocytochemistry

Fri Jul 08 00:00:00 EDT 2022

Mechanism of Multi-Organ Injury in Experimental COVID-19 and Its Inhibition by a Small Molecule Peptide.

Frontiers in pharmacology

Paidas MJ,Sampath N,Schindler EA,Cosio DS,Ndubizu CO,Shamaladevi N,Kwal J,Rodriguez S,Ahmad A,Kenyon NS,Jayakumar AR

MA5-29981 was used in Immunohistochemistry (Paraffin) to suggest the possible involvement of altered aquaporins and the subsequent edema, likely mediated by the virus-induced inflammatory and oxidative stress response, in the pathogenesis of COVID- 19 and the potential of SPIKENET as a therapeutic option.

Sat Jul 16 00:00:00 EDT 2022

SARS-CoV-2 infects an in vitro model of the human developing pancreas through endocytosis.

iScience

Szlachcic WJ,Dabrowska A,Milewska A,Ziojla N,Blaszczyk K,Barreto-Duran E,Sanak M,Surmiak M,Owczarek K,Grzanka D,Durzynska J,Pyrc K,Borowiak M

MA5-29981 was used in ELISA, Immunocytochemistry, Western Blot, Immunohistochemistry to investigate whether SARS-CoV-2 infection may affect pancreas development, possibly causing lifelong health consequences.

Fri Jul 15 00:00:00 EDT 2022

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines.

Nature communications

Wang L,Kainulainen MH,Jiang N,Di H,Bonenfant G,Mills L,Currier M,Shrivastava-Ranjan P,Calderon BM,Sheth M,Mann BR,Hossain J,Lin X,Lester S,Pusch EA,Jones J,Cui D,Chatterjee P,Jenks MH,Morantz EK,Larson GP,Hatta M,Harcourt JL,Tamin A,Li Y,Tao Y,Zhao K,Lacek K,Burroughs A,Wang W,Wilson M,Wong T,Park SH,Tong S,Barnes JR,Tenforde MW,Self WH,Shapiro NI,Exline MC,Files DC,Gibbs KW,Hager DN,Patel M,Halpin AL,McMullan LK,Lee JS,Xia H,Xie X,Shi PY,Davis CT,Spiropoulou CF,Thornburg NJ,Oberste MS,Dugan VG,Wentworth DE,Zhou B

MA5-29981 was used in Immunocytochemistry-immunoflourescence to conclude that vaccination remains an effective strategy during the COVID-19 pandemic.

Wed Jul 27 00:00:00 EDT 2022

Intronic regulation of SARS-CoV-2 receptor (ACE2) expression mediated by immune signaling and oxidative stress pathways.

iScience

Richard D,Muthuirulan P,Aguiar J,Doxey AC,Banerjee A,Mossman K,Hirota J,Capellini TD

MA5-29981 was used in Western Blotting to study the mechanisms of ACE2 regulation and the response to immune signaling and oxidative-stress pathways.

Fri Jul 15 00:00:00 EDT 2022

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models.

Science translational medicine

Hajnik RL,Plante JA,Liang Y,Alameh MG,Tang J,Bonam SR,Zhong C,Adam A,Scharton D,Rafael GH,Liu Y,Hazell NC,Sun J,Soong L,Shi PY,Wang T,Walker DH,Sun J,Weissman D,Weaver SC,Plante KS,Hu H

MA5-29981 was used in Western Blotting to suggest that combined mRNA-S+N vaccination is an effective approach for promoting broad protection against SARS-CoV-2 variants.

Wed Sep 14 00:00:00 EDT 2022

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies.

NPJ vaccines

Zhong C,Xia H,Adam A,Wang B,Hajnik RL,Liang Y,Rafael GH,Zou J,Wang X,Sun J,Soong L,Barrett ADT,Weaver SC,Shi PY,Wang T,Hu H

MA5-29981 was used in Western Blotting to indicate that T-cell immunity is also likely critical for protection against SARS-CoV-2 infection in addition to neutralizing antibodies.

Mon Nov 29 00:00:00 EST 2021

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies.

NPJ vaccines

Zhong C,Xia H,Adam A,Wang B,Hajnik RL,Liang Y,Rafael GH,Zou J,Wang X,Sun J,Soong L,Barrett ADT,Weaver SC,Shi PY,Wang T,Hu H

MA5-29981 was used in Western Blotting to indicate that T-cell immunity is also likely critical for protection against SARS-CoV-2 infection in addition to neutralizing antibodies.

Mon Nov 29 00:00:00 EST 2021

Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities.

Nature communications

Kruse T,Benz C,Garvanska DH,Lindqvist R,Mihalic F,Coscia F,Inturi R,Sayadi A,Simonetti L,Nilsson E,Ali M,Kliche J,Moliner Morro A,Mund A,Andersson E,McInerney G,Mann M,Jemth P,Davey NE,Överby AK,Nilsson J,Ivarsson Y

MA5-29981 was used in Western Blot to describe a viral peptide discovery approach covering 23 coronavirus strains that provides high resolution information on direct virus-host interactions.

Fri Nov 19 00:00:00 EST 2021

Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities.

Nature communications

MA5-29981 was used in Western Blot to describe a viral peptide discovery approach covering 23 coronavirus strains that provides high resolution information on direct virus-host interactions.

Fri Nov 19 00:00:00 EST 2021

Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CL^pro substrate degradome.

Cell reports

Pablos I,Machado Y,de Jesus HCR,Mohamud Y,Kappelhoff R,Lindskog C,Vlok M,Bell PA,Butler GS,Grin PM,Cao QT,Nguyen JP,Solis N,Abbina S,Rut W,Vederas JC,Szekely L,Szakos A,Drag M,Kizhakkedathu JN,Mossman K,Hirota JA,Jan E,Luo H,Banerjee A,Overall CM

Published figure using SARS/SARS-CoV-2 Nucleocapsid monoclonal antibody (Product # MA5-29981) in Western Blot

Tue Oct 26 00:00:00 EDT 2021

Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses.

iScience

Banerjee A,El-Sayes N,Budylowski P,Jacob RA,Richard D,Maan H,Aguiar JA,Demian WL,Baid K,D'Agostino MR,Ang JC,Murdza T,Tremblay BJ,Afkhami S,Karimzadeh M,Irving AT,Yip L,Ostrowski M,Hirota JA,Kozak R,Capellini TD,Miller MS,Wang B,Mubareka S,McGeer AJ,McArthur AG,Doxey AC,Mossman K

Fri May 21 00:00:00 EDT 2021

Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses.

iScience

Fri May 21 00:00:00 EDT 2021

Bioinformatics

Protein Aliases: COVID-19 nucleocapsid; COVID19 Nucleocapsid; COVID19 Spike nucleocapsid; SARS-CoV-2 N

View more View less

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

SARS/SARS-CoV-2 Nucleocapsid Monoclonal Antibody (05)

SARS/SARS-CoV-2 Nucleocapsid Antibody (MA5-29981) in ICC/IF

Product Details

MA5-29981

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Immunocytochemistry (ICC/IF)

Flow Cytometry (Flow)

ELISA (ELISA)

Species Reactivity

Published species

Host/Isotype

Class

Type

Clone

Immunogen

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!